3 Australian Penny Stocks Backed By Real Revenue And Balance Sheet Strength

With global 10 year bond yields drifting higher as inflation worries linger, many investors are rethinking how much risk they really want in smaller stocks. That is where the Financially Fit Penny Stocks screener becomes interesting. It filters for low priced companies that still show balance sheet strength. This article highlights three stocks from the screener that aim to combine penny stock potential with more disciplined financial foundations.

The three stocks in this article are just a small sample, and the full Financially Fit Penny Stocks screen surfaced 398 more companies with equally compelling stories that are not covered here. If you want to go straight to the source and identify, analyze and rank your own ideas, head into the Financially Fit Penny Stocks screener.

Ora Banda Mining (ASX:OBM)

Ora Banda Mining is a gold producer and explorer in Western Australia, with the fully owned Davyhurst Gold Project providing the key cash generating asset that aligns it with the Financially Fit Penny Stocks theme. The company generates all of its A$807.5 million in sales from gold production and exploration in Australia, and also explores for nickel and copper as smaller side projects. At a market cap of about A$3.0b, Ora Banda Mining sits at the larger end of the penny stock universe while still offering exposure to an early stage growth story.

Ora Banda Mining brings something many penny stocks lack: a producing gold project that already throws off cash and is supported by growing resources and reserves. Earnings quality is described as high and return on equity above 40% points to efficient use of capital, yet the stock is priced well below some estimates of fair value, which may appeal to value focused investors. The flip side is that margins have come down from last year and the business leans on external borrowing, so production hiccups or weaker gold prices could quickly bite. For investors willing to balance this trade off, the combination of real assets, strong profitability metrics and valuation gap makes Ora Banda Mining worth a closer look.

Ora Banda Mining’s high return on equity and producing gold asset could be masking a much bigger story about how the market is pricing its risks and rewards. For a more detailed view, see the full analysis in the 3 key rewards and 1 important warning sign

Alkane Resources (ASX:ALK)

Alkane Resources is a multi mine gold and antimony producer that fits the Financially Fit Penny Stocks theme through its cash generating gold operations, particularly Tomingley and Northern Molong, which anchor the business in real production rather than pure exploration. Revenue is spread across three mines, with A$417 million from Tomingley, A$270 million from Costerfield and A$249 million from Bjorkdal, all recorded in Australia reporting terms, and the company carries a market cap of about A$2.6b. This scale provides Alkane Resources with more funding options than many junior companies, while still leaving room for growth associated with high grade Costerfield drilling, the large Boda Kaiser gold copper project and ongoing dividends and buybacks. These are set against risks such as underground mining complexity, higher cost operations and a relatively new board and management team.

Alkane Resources appears to be a producer whose current cash generating mines may only be half the story. Get the full picture in the analysis report for Alkane Resources

Sigma Healthcare (ASX:SIG)

Sigma Healthcare runs one of Australia’s largest pharmacy wholesale and franchise networks, supplying medicines and health products to Chemist Warehouse, Amcal, Discount Drug Stores and PriceSave, which aligns directly with the Financially Fit Penny Stocks focus on recurring, cash generative operations. The company reports about A$10.8b of healthcare revenue, largely from these wholesale and distribution activities, and also offers its MPS Connect medication management service and online retail. With a market cap of roughly A$30.9b, Sigma Healthcare is a sizeable business relative to many stocks investors might think of as “penny” opportunities.

Investors looking at Sigma Healthcare are getting a healthcare distributor whose core pharmacy wholesale and franchising engine provides steady revenue tied to everyday prescriptions, plus an MPS Connect platform that deepens relationships with pharmacy clients. At the same time, the push into new domestic and international stores, GLP 1 exposure, higher margin exclusive labels and a A$100m synergy program create room for profit improvement, but also bring execution and working capital risks if store rollouts or inventory turn do not go to plan. The mix of recurring cash flows, active expansion and a relatively new leadership team means the next few years could be pivotal for how the market ultimately values Sigma Healthcare’s progress.

Sigma Healthcare’s expanding pharmacy network and recurring A$10.8b revenue stream could be masking how the story is changing right now. See how the market is framing that shift in the analyst forecasts for Sigma Healthcare

Seeking Fresh Alternatives Before Others Catch On

Markets can change quickly and new stories that gain attention rarely remain unnoticed for long. Review these fresh stock ideas before momentum is fully recognized and consider them while they are still developing.

• Identify potential early leaders in gold and precious metals by screening curated producers through the 34 elite gold producer stocks while they are still flying under most investors radars.
• Follow the build out of critical grid and electrification projects by running the 38 power grid technology and infrastructure stocks and focusing on companies involved in essential energy infrastructure.
• Monitor opportunities related to intelligent automation by using the 38 robotics and automation stocks to find curated stocks in areas where robotics and real world demand intersect.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com